Zealand Pharma A/S (OTCMKTS:ZLDPF) Stock Price Down 2.5% – Here’s What Happened

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s stock price traded down 2.5% during mid-day trading on Friday . The stock traded as low as $96.81 and last traded at $97.25. 2,221 shares traded hands during trading, an increase of 63% from the average session volume of 1,360 shares. The stock had previously closed at $99.70.

Analysts Set New Price Targets

Separately, JPMorgan Chase & Co. began coverage on shares of Zealand Pharma A/S in a research report on Friday, November 8th. They set an “overweight” rating for the company.

Zealand Pharma A/S Price Performance

The company has a market cap of $5.01 billion, a price-to-earnings ratio of -40.02 and a beta of 0.89. The company has a current ratio of 35.49, a quick ratio of 35.49 and a debt-to-equity ratio of 0.03. The company has a fifty day moving average price of $108.12 and a two-hundred day moving average price of $119.91.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.